GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (ASX:CUV) » Definitions » Cyclically Adjusted PS Ratio

Clinuvel Pharmaceuticals (ASX:CUV) Cyclically Adjusted PS Ratio : 15.93 (As of Nov. 10, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Clinuvel Pharmaceuticals Cyclically Adjusted PS Ratio?

As of today (2024-11-10), Clinuvel Pharmaceuticals's current share price is A$13.70. Clinuvel Pharmaceuticals's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Jun24 was A$0.86. Clinuvel Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 15.93.

The historical rank and industry rank for Clinuvel Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:

ASX:CUV' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 15.55   Med: 83.75   Max: 240.94
Current: 15.98

During the past 13 years, Clinuvel Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 240.94. The lowest was 15.55. And the median was 83.75.

ASX:CUV's Cyclically Adjusted PS Ratio is ranked worse than
78.7% of 460 companies
in the Biotechnology industry
Industry Median: 5.665 vs ASX:CUV: 15.98

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Clinuvel Pharmaceuticals's adjusted revenue per share data of for the fiscal year that ended in Jun24 was A$1.727. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is A$0.86 for the trailing ten years ended in Jun24.

Shiller PE for Stocks: The True Measure of Stock Valuation


Clinuvel Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Clinuvel Pharmaceuticals Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 101.42 87.10 29.82 26.55 17.93

Clinuvel Pharmaceuticals Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.82 - 26.55 - 17.93

Competitive Comparison of Clinuvel Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clinuvel Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Clinuvel Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Clinuvel Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=13.70/0.86
=15.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clinuvel Pharmaceuticals's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Jun24 is calculated as:

For example, Clinuvel Pharmaceuticals's adjusted Revenue per Share data for the fiscal year that ended in Jun24 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun24 (Change)*Current CPI (Jun24)
=1.727/128.9064*128.9064
=1.727

Current CPI (Jun24) = 128.9064.

Clinuvel Pharmaceuticals Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.067 99.838 0.087
201606 0.137 100.859 0.175
201706 0.333 102.809 0.418
201806 0.515 104.945 0.633
201906 0.627 106.617 0.758
202006 0.646 106.246 0.784
202106 0.939 110.332 1.097
202206 1.269 117.112 1.397
202306 1.512 124.170 1.570
202406 1.727 128.906 1.727

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Clinuvel Pharmaceuticals  (ASX:CUV) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Clinuvel Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Clinuvel Pharmaceuticals Business Description

Address
535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Clinuvel Pharmaceuticals Headlines

No Headlines